August 2, 2006 -- Abbott Laboratories received FDA approval of another new use for its rheumatoid arthritis drug Humira: ankylosing spondilitis, an auto-immune disease that affects the spine and large joints and causes back pain and stiffness. Humira (adalimumab) is already indicated for RA and Psoriatic Arthritis and is seeking approval for Crohn’s Disease and other inflammatory indications. We look at this remarkably successful drug that seems to have a long and profitable life ahead of it...
